Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

Chinese Patent Office
Medtronic
UBS
AstraZeneca
Harvard Business School
Citi

Generated: September 23, 2019

DrugPatentWatch Database Preview

Patent: 8,642,314

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,642,314
Title:Optimization of expression of parvoviral rep and cap proteins in insect cells
Abstract: The present invention relates to the improved production of recombinant parvoviral virions in insect cells. In particular, the invention relates to an improved process for the production of recombinant parvoviral virions in insect cells, wherein the full/empty parvoviral virion ratio is increased. The invention also relates to the production of parvoviral vectors that may be used in gene therapy and to improvements in expression of the viral Rep proteins that increase the productivity of parvoviral vectors.
Inventor(s): Bakker; Andrew Christian (Almere, NL), Hermens; Wilhelmus Theodorus Johannes Maria Christiaan (Almere, NL), Noordman; Yvet (Utrecht, NL)
Assignee: Amsterdam Molecular Therapeutics (AMT) B.V. (NL)
Application Number:12/918,460
Patent Claims:see list of patent claims

Details for Patent 8,642,314

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Schering INTRON A interferon alfa-2b VIAL 103132 001 1986-06-04 ➤ Sign Up Amsterdam Molecular Therapeutics (AMT) B.V. (NL) 2028-02-19 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 002 1986-06-04 ➤ Sign Up Amsterdam Molecular Therapeutics (AMT) B.V. (NL) 2028-02-19 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 003 1986-06-04 ➤ Sign Up Amsterdam Molecular Therapeutics (AMT) B.V. (NL) 2028-02-19 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Merck
Covington
AstraZeneca
UBS
Chinese Patent Office
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.